Clinical trials: Hepato Carcinoma
Hepatocellular Carcinoma
Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
The study is designed to determine whether loading doxorubicin (a type of chemotherapy), when loaded onto a drug eluting microsphere will result in increased destruction of a tumor.
- Trial name
- NCT01116635
- Testing
- doxorubicin, superabsorbent polymer microspheres, embolotherapy
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Hepato Cellular Carcinoma (HCC)
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine…
- Trial name
- IMPACT-TACE (NCT07302919)
- Testing
- DEB-DoxNic-TACE, current standard of care
- Where
- 3 sites in Switzerland
- Volunteers
- 152 people
- Sponsor
- University Hospital, Basel, Switzerland
Hepato Cellular Carcinoma (HCC)
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT06960863
- Testing
- fibroscan
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Tanta University
Hepatocellular Carcinoma
Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency
HCC (Hepato-cellular Carcinoma) is the fifth most frequent cancer in humans and its prevalence is growing. The most effective treatment of HCC is surgical and includes resection and liver transplantation; however, only 20% of the…
- Trial name
- HCC (NCT01322477)
- Testing
- F18-FDG PET/CT
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Hadassah Medical Organization
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05236686
- Testing
- Hepato-celiac lymphadenectomy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Hepato Cellular Carcinoma (HCC)
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
This is a single-arm, phase II clinical trial evaluating the safety and efficacy of PD-L1 antibody combined with bevacizumab and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced unresectable hepatocellular…
- Trial name
- NCT06742424
- Testing
- PD-L1 antibody, Bevacizumab, HAIC-FOLFOX
- Where
- China
- Volunteers
- 36 people
- Sponsor
- West China Hospital
Hepato Cellular Carcinoma (HCC)
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06848556
- Testing
- tirapazamine, Transarterial Embolization, TACE
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Hepato Cellular Carcinoma (HCC), Immunotherapy
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.
- Trial name
- NCT07461675
- Testing
- Atezolizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Geneva, Switzerland
Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301…
- Trial name
- NCT07494435
- Testing
- WGI-0301, Nivolumab (240 mg)
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age…
- Conditions
- Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos
- Trial name
- CLARITY (NCT07903571)
- Testing
- Research blood samples
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Hepato-cellular Carcinoma
Novel Biomarker Assay for Biomarker Assay for HCC Detection
The primary purpose of this study is to assess the performance feasibility of Genetron's novel HCC liquid biopsy biomarkers assay for early detection.
- Trial name
- GTH_HCC (NCT05494853)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genetron Health
Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato…
- Trial name
- CHOC (NCT06990659)
- Testing
- Ambulatory care, Conventional inpatient care
- Where
- 19 sites in France
- Volunteers
- 206 people
- Sponsor
- University Hospital, Angers
Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07267806
- Testing
- Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Linhui Peng
Hepato Cellular Carcinoma (HCC)
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S.
- Trial name
- NCT06608940
- Testing
- BC3402, Durvalumab, Tremelimumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes The goal of this clinical trial is to evaluate of the involvement of Neutrophil extracellular traps in the evolution of…
- Conditions
- Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation, Anesthesia, Lidocaine Infusion
- Trial name
- NCT07207304
- Testing
- Anesthesia, Anesthesia induction with TCI, sevoflurane anesthesia
- Where
- Romania
- Volunteers
- 153 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Hepato Cellular Carcinoma
IIT2025-03-YANG-LIFT-HCC
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC).
- Trial name
- NCT07489976
- Testing
- STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ju Dong Yang
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Training and Validation Data Collection Study
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD TVDCS (NCT06675604)
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris